Refine by
Tumor Microenvironment Articles & Analysis
57 news found
CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of its new Tumor Organoid & CAF Co-culture services to provide researchers with a more physiologically relevant in vitro tumor model, enabling a deeper understanding of tumor-stromal interactions and the development of more effective cancer therapies. Although cancer ...
Watertown, MA - June 29, 2025 - Biopharma PEG, a leading innovator in high-quality polyethylene glycol (PEG) derivatives, today announced it has successfully obtained Drug Master File (DMF) approval from the U.S. Food and Drug Administration (FDA) for its self-developed HZ-PEG-HZ (1K) product. The assigned DMF number is 041864. This significant achievement underscores Biopharma PEG's robust ...
Alfa Cytology, a premier contract research organization, recently launched its full-scale pancreatic cancer research services with robust platforms, powerful analytics, and cross-platform collaborations. Pancreatic cancer (PC) is a severe disease that is difficult to diagnose in the early stages due to its complex and hidden nature. Studies found that the incidence rate of PC has been ...
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer progresses novel research ...
ByBayer AG
ATG-037 is Antengene’s oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD’s anti-PD-1 therapy The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic solid tumors The study of ATG-037 monotherapy started enrolling patients in Q2 2022 and will ...
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. The company launches the drug-resistant metabolomics research service for oncology research and infectious disease studies regarding drug resistance. Drug therapy is one of the ...
Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRPα monoclonal antibody ES004, PD-L1/SIRPα bispecific antibody ...
ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to enter clinical studies in Australia and China, thus becoming the first oral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. ATG-037 IND in Australia has been started enrolling in that phase I study. -The STAMINA-001 study will evaluate ATG-037 as a ...
IO-108 is being studied as a monotherapy and in combination with select anti-PD-1 antibodies in multiple expansion cohorts of solid tumors Clinical supply agreement with Regeneron accelerates Immune-Onc’s solid tumor clinical development program Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 DAEJEON, South Korea, October 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology ...
Company announces completion of Phase 1 dose escalation ahead of schedule for IO-108, a first-in-class antibody targeting LILRB2 (ILT4) Signals of clinical activity observed in multiple tumor types for IO-108 as a single agent and in combination with an anti-PD-1 Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced it has entered into a clinical trial collaboration and supply agreement with to evaluate Immune-Onc’s first-in-class myeloid checkpoint inhibitors, IO-108 and IO-202, in combination with ...
IO-108 is the first LILRB2-targeting antibody administered to Chinese patients Implementation of IO-108 program in China initiates Immune-Onc’s global clinical development plan; Phase 1 trial has completed dose escalation in the U.S. in solid tumor patients Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel ...
Researchers in the laboratory of Yulia Nefedova, M.D., Ph.D., at The Wistar Institute and collaborators at the Jubilant Therapeutics Inc. have uncovered a novel mechanism by which protein arginine deiminase 4 (PAD4) in neutrophils promotes cancer progression. The paper also found that inhibition of this function of PAD4 reduces primary tumor growth and metastasis and enhances checkpoint inhibitor ...
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patients Company to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography (“PET”) hypoxia imaging methodology with data expected ...
ByCervoMed
Xilis, Inc., a pioneering company developing its MicroOrganoSphere™ (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that it is participating in the recently announced public-private Oncode-PACT. Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an ...
Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - Senti Biosciences, Inc. ...
Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, announced today that breast cancer oncologist Daniel F. Hayes, MD, FACP, FASCO, has joined the company’s Clinical Advisory Board (CAB). Dr. Hayes is a Professor of Internal Medicine, the Stuart B. Padnos Professor ...
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT05387265). CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on ...